PT - JOURNAL ARTICLE AU - Krishna P. Reddy AU - Kieran P. Fitzmaurice AU - Justine A. Scott AU - Guy Harling AU - Richard J. Lessells AU - Christopher Panella AU - Fatma M. Shebl AU - Kenneth A. Freedberg AU - Mark J. Siedner TI - Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa AID - 10.1101/2021.05.07.21256852 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.07.21256852 4099 - http://medrxiv.org/content/early/2021/05/12/2021.05.07.21256852.short 4100 - http://medrxiv.org/content/early/2021/05/12/2021.05.07.21256852.full AB - Low- and middle-income countries are implementing COVID-19 vaccination strategies in light of varying and uncertain vaccine efficacies and costs, supply shortages, and resource constraints. We used a microsimulation model to evaluate clinical outcomes and cost-effectiveness of a COVID-19 vaccination program in South Africa. We varied vaccination coverage, pace, acceptance, effectiveness, and cost as well as epidemic dynamics. Providing vaccine to at least 40% of the population and prioritizing accelerated vaccine rollout prevented >9 million infections and >73,000 deaths and reduced costs due to fewer hospitalizations. Further, the vaccination program was cost-saving even at the lowest examined levels of acceptance (50%), effectiveness against infection (20%), effectiveness against symptomatic disease (30%), and effectiveness against severe/critical disease requiring hospitalization (40%), and with vaccination costs of up to USD25/person. In summary, a COVID-19 vaccination program would reduce both deaths and health care costs in South Africa across a wide range of assumptions. Vaccination program implementation factors, including prompt procurement, distribution, and rollout, are likely more influential than characteristics of the vaccine itself in maximizing public health benefits and economic efficiency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R37 AI058736-16S1] and by the Wellcome Trust [Grant number 210479/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. The funding sources had no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General BrighamAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis modeling study involved the use of published or publicly available data. The data used and the sources are described in the Manuscript and Supplement. No primary data were collected for this study. Model flowcharts are in the Supplement.